NasdaqCM:NVIV

Stock Analysis Report

InVivo Therapeutics Holdings

Executive Summary

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has InVivo Therapeutics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NVIV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.3%

NVIV

0.5%

US Medical Equipment

0.06%

US Market


1 Year Return

-83.0%

NVIV

20.6%

US Medical Equipment

19.4%

US Market

Return vs Industry: NVIV underperformed the US Medical Equipment industry which returned 20.6% over the past year.

Return vs Market: NVIV underperformed the US Market which returned 19.4% over the past year.


Shareholder returns

NVIVIndustryMarket
7 Day1.3%0.5%0.06%
30 Day-27.9%0.1%1.1%
90 Day51.0%7.5%8.9%
1 Year-83.0%-83.0%21.6%20.6%21.9%19.4%
3 Year-99.8%-99.8%81.5%76.4%48.9%39.3%
5 Year-99.9%-99.9%114.9%92.3%71.9%53.1%

Price Volatility Vs. Market

How volatile is InVivo Therapeutics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InVivo Therapeutics Holdings undervalued compared to its fair value and its price relative to the market?

0.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NVIV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NVIV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NVIV is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: NVIV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NVIV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NVIV is good value based on its PB Ratio (0.3x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is InVivo Therapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

60.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NVIV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NVIV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NVIV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if NVIV's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if NVIV's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NVIV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has InVivo Therapeutics Holdings performed over the past 5 years?

6.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NVIV is currently unprofitable.

Growing Profit Margin: NVIV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NVIV is unprofitable, but has reduced losses over the past 5 years at a rate of 6.3% per year.

Accelerating Growth: Unable to compare NVIV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NVIV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.1%).


Return on Equity

High ROE: NVIV has a negative Return on Equity (-139.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is InVivo Therapeutics Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: NVIV's short term assets ($8.5M) exceed its short term liabilities ($2.1M).

Long Term Liabilities: NVIV's short term assets ($8.5M) exceed its long term liabilities ($1.2M).


Debt to Equity History and Analysis

Debt Level: NVIV is debt free.

Reducing Debt: NVIV has no debt compared to 5 years ago when its debt to equity ratio was 14.3%.


Balance Sheet

Inventory Level: NVIV has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if NVIV's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NVIV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NVIV has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.1% each year.


Next Steps

Dividend

What is InVivo Therapeutics Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NVIV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NVIV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NVIV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NVIV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NVIV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Rich Toselli (61yo)

2.2yrs

Tenure

US$741,948

Compensation

Dr. Richard M. Toselli, also known as Rich, M.D., has been serves as President, Chief Executive Officer and Director of InVivo Therapeutics Holdings Corp. (“InVivo”) since February 2, 2018 and has been its ...


CEO Compensation Analysis

Compensation vs Market: Rich's total compensation ($USD741.95K) is above average for companies of similar size in the US market ($USD519.76K).

Compensation vs Earnings: Rich's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Richard Toselli
President2.2yrsUS$741.95k0.44% $17.6k
Robert Langer
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Joseph Vacanti
Co-Founder15.1yrsno datano data
Richard Christopher
Chief Financial Officer1.1yrsno data0.29% $11.5k
William D'Agostino
Senior Vice President of Operations5.7yrsno datano data
Louis Vaickus
Consultant3.3yrsno datano data

4.5yrs

Average Tenure

66yo

Average Age

Experienced Management: NVIV's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Richard Toselli
President2.2yrsUS$741.95k0.44% $17.6k
Robert Langer
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Robert Rosenthal
Independent Director0.3yrsno datano data
C. Merrifield
Independent Chair of the Board2.2yrsUS$81.44k0.00054% $21.6
Daniel Marshak
Independent Director5.4yrsUS$56.86kno data
Richard Roberts
Independent Director & Member of Scientific Advisory Board9.3yrsUS$50.19k0.052% $2.1k
V. Edgerton
Member of Scientific Advisory Board0yrsno datano data
Christina Morrison
Independent Director3.7yrsUS$60.19kno data
James Guest
Member of Scientific Advisory Board4.7yrsno datano data

3.7yrs

Average Tenure

62yo

Average Age

Experienced Board: NVIV's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 205.1%.


Top Shareholders

Company Information

InVivo Therapeutics Holdings Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InVivo Therapeutics Holdings Corp.
  • Ticker: NVIV
  • Exchange: NasdaqCM
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$3.992m
  • Shares outstanding: 550.65k
  • Website: https://www.invivotherapeutics.com

Number of Employees


Location

  • InVivo Therapeutics Holdings Corp.
  • One Kendall Square
  • Floor 4
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NVIVNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2010
04IBDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2010

Biography

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 01:07
End of Day Share Price2020/02/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.